Actively Recruiting
Randomized, Double-Blind Study of Xolatryp Infusion in Adults With STEMI Undergoing Primary PCI to Prevent Reperfusion Injury
Led by Nyrada Pty Ltd · Updated on 2026-11-04
300
Participants Needed
8
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of a medicine called Xolatryp in adults who have experienced a ST elevation myocardial infarction heart attack and are undergoing primary percutaneous coronary intervention PCI. The study aims to compare cardiac outcomes between participants receiving Xolatryp and those receiving a placebo. This is a Phase 2, randomized, double-blind trial involving adults aged 40 to 75 years with first-time STEMI. Participants are randomly assigned to one of two groups. One group receives a single 6-hour continuous intravenous infusion of Xolatryp during their primary PCI treatment, while the other group receives a placebo infusion that looks like Xolatryp but contains no medicine. All participants receive standard therapy alongside the study interventions. The study lasts about 30 days, including treatment and follow-up. During the study, participants have blood samples taken to analyze heart health and drug levels, and undergo electrocardiograms ECG, echocardiograms, and cardiac magnetic resonance CMR imaging. Researchers monitor adverse events and cardiac injury markers, such as arrhythmias and ST-segment elevation resolution. Participants are followed up by telephone and attend one study visit on day 30. General health is regularly assessed throughout the study.
CONDITIONS
Brief Title
Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction
Research Team
A
Alexandra Suchowerska Director, Clinical Operations and Regulatory Affairs, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here